Background and objectives: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms...
-
February 21, 2023 (v1)Journal articleUploaded on: October 9, 2024
-
October 11, 2023 (v1)Publication
Introduction: Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe autoimmune demyelinating disease of the optic nerves and spinal cord affecting 0.4-4/100,000 individuals worldwide. Recently, an international consensus was reached to harmonize diagnosis criteria of neuroinflammatory diseases. The majority of patients with NMOSD are...
Uploaded on: October 12, 2024